GO:0019287 isopentenyl diphosphate biosynthetic process, mevalonate pathway: Isoprenoid Precursor Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019287 describes the mevalonate (MVA) pathway that converts acetyl-CoA to isopentenyl diphosphate (IPP), the universal five-carbon building block of all isoprenoids.
• The pathway proceeds through sequential intermediates: acetoacetyl-CoA, HMG-CoA, mevalonate, mevalonate-5-phosphate, mevalonate-5-diphosphate, and finally IPP.
• IPP is the fundamental unit for cholesterol, steroid hormones, coenzyme Q10, dolichols, heme A, and prenylated proteins.
• The MVA pathway is distinct from the mevalonate-independent methylerythritol phosphate (MEP) pathway found in most bacteria and plant plastids.
• Dysregulation of the MVA pathway is linked to liver cancer progression through suppression of ferroptosis via CoQ10 and selenocysteine-tRNA modification.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of MVA pathway genes in health and disease.
Description
The mevalonate pathway for isopentenyl diphosphate biosynthesis (GO:0019287) is a central metabolic route that converts acetyl-CoA into isopentenyl diphosphate (IPP), the fundamental five-carbon unit required for all isoprenoid biosynthesis. This pathway, also known as the acetate-mevalonate (Ac-MVA) pathway, is essential in eukaryotes, archaea, and some bacteria, and it supplies precursors for cholesterol, steroid hormones, bile acids, coenzyme Q10, dolichols, heme A, and prenylated proteins. The mevalonate pathway is mechanistically distinct from the mevalonate-independent methylerythritol phosphate (MEP) pathway that operates in most bacteria and plant plastids. Understanding GO:0019287 is therefore critical for researchers in cancer metabolism, cardiovascular biology, infectious disease, and metabolic engineering.
isopentenyl diphosphate biosynthetic process, mevalonate pathway At A Glance
| GO ID | GO:0019287 |
|---|---|
| GO term | isopentenyl diphosphate biosynthetic process, mevalonate pathway |
| Ontology | biological_process |
| Synonym | acetate-mevalonate pathway; Ac-MVA pathway; mevalonate pathway; MVA pathway |
| Major function | Conversion of acetyl-CoA to isopentenyl diphosphate (IPP) via mevalonate intermediates |
| End product | Isopentenyl diphosphate (IPP), the universal isoprenoid precursor |
| Key intermediates | Acetoacetyl-CoA, HMG-CoA, mevalonate, mevalonate-5-phosphate, mevalonate-5-diphosphate |
| Pathway type | Mevalonate-dependent (MVA) pathway, distinct from the MEP/DOXP pathway |
| Cellular location | Cytosol and peroxisomes in eukaryotes; cytoplasm in bacteria |
What Is GO:0019287?
GO:0019287 is defined as the chemical reactions and pathways resulting in the formation of isopentenyl diphosphate via the intermediate mevalonate. This pathway converts acetate, in the form of acetyl-CoA, to isopentenyl diphosphate (IPP), the fundamental unit in isoprenoid biosynthesis, through a series of mevalonate intermediates. The pathway is synonymous with the acetate-mevalonate pathway, Ac-MVA pathway, and mevalonate pathway for IPP synthesis.
Why Is isopentenyl diphosphate biosynthetic process, mevalonate pathway Important in Cell Biology?
GO:0019287 is fundamentally important because it produces IPP, the essential building block for thousands of isoprenoid compounds that mediate membrane integrity, protein prenylation, electron transport, and hormone signaling. The pathway is a validated therapeutic target in cardiovascular disease (statins), and its dysregulation contributes to cancer, neurodegeneration, and metabolic disorders. Moreover, the MVA pathway is a major focus in metabolic engineering for production of isoprenoids such as isopentenol and artemisinin precursors.
• Supplies IPP for cholesterol and steroid hormone biosynthesis, making it a target of statin drugs.
• Provides precursors for coenzyme Q10 (CoQ10), critical for mitochondrial electron transport and ferroptosis suppression.
• Generates dolichols required for N-linked protein glycosylation.
• Produces isoprenyl groups for prenylation of small GTPases such as RAS and RHO.
• Contributes to heme A and vitamin K synthesis.
• Dysregulated in liver cancer, where it suppresses ferroptosis via CoQ10 and selenocysteine-tRNA modification.
• Essential in pathogenic bacteria such as Pseudomonas mevalonii, offering antimicrobial targets.
• Engineered in bioreactors for isopentenol and other isoprenoid production.
• Distinct from the MEP pathway, enabling selective targeting in plants and bacteria.
• Mitochondrial CoQ export under cholesterol biosynthetic stress is limited by mitochondria.
What Happens During isopentenyl diphosphate biosynthetic process, mevalonate pathway?
Step 1: Condensation of Acetyl-CoA to Acetoacetyl-CoA
In simple terms: Two acetyl-CoA molecules join to form acetoacetyl-CoA, the first committed step.
The mevalonate pathway begins with the condensation of two molecules of acetyl-CoA to form acetoacetyl-CoA, catalyzed by acetoacetyl-CoA thiolase. This step is conserved across eukaryotes and bacteria that use the MVA pathway. In engineered systems, this reaction is often the first module in multienzyme bioreactors for isoprenoid production.
Step 2: HMG-CoA Synthesis and Reduction to Mevalonate
In simple terms: Acetoacetyl-CoA is converted to HMG-CoA, then reduced to mevalonate, the rate-limiting step.
Acetoacetyl-CoA condenses with a third acetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA), which is then reduced to mevalonate by HMG-CoA reductase (HMGR). This reduction is the rate-limiting and most regulated step of the pathway. Class II HMGR enzymes, such as that from Pseudomonas mevalonii, have been structurally and biochemically characterized, revealing distinct catalytic mechanisms.
Step 3: Phosphorylation to Mevalonate-5-Diphosphate
In simple terms: Mevalonate is phosphorylated twice to form mevalonate-5-diphosphate.
Mevalonate is sequentially phosphorylated by mevalonate kinase and phosphomevalonate kinase to yield mevalonate-5-phosphate and then mevalonate-5-diphosphate. These phosphorylation steps are essential for activation prior to decarboxylation. In some organisms, an IPP-bypass pathway can circumvent these steps for isopentenol production.
Step 4: Decarboxylation to Isopentenyl Diphosphate (IPP)
In simple terms: Mevalonate-5-diphosphate loses CO2 to become IPP, the final product.
Mevalonate-5-diphosphate undergoes ATP-dependent decarboxylation catalyzed by mevalonate diphosphate decarboxylase to form isopentenyl diphosphate (IPP). IPP is the fundamental unit for all isoprenoid biosynthesis. This terminal step is a key target for metabolic engineering and inhibitor design.
Alternative MVA-Independent Pathway
In simple terms: Some organisms use a different route (MEP/DOXP) that does not require mevalonate.
The mevalonate-independent methylerythritol phosphate (MEP) pathway, also called the deoxyxylulose phosphate (DOXP) pathway, operates in most bacteria and plant plastids and produces IPP from pyruvate and glyceraldehyde-3-phosphate. Isopentenyl monophosphate kinase catalyzes the terminal step in a mevalonate-independent route in some organisms. This pathway is distinct from GO:0019287 and is not the subject of this article.
Key Genes Involved in GO:0019287 isopentenyl diphosphate biosynthetic process, mevalonate pathway
The following genes and enzymes are core components of the mevalonate pathway for IPP biosynthesis (GO:0019287).
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACAT1 | Acetoacetyl-CoA thiolase; condenses acetyl-CoA | Target for metabolic engineering and cancer metabolism studies |
| ACAT2 | Cytosolic acetoacetyl-CoA thiolase | Isoform-specific roles in lipogenesis |
| HMGCS1 | HMG-CoA synthase 1; synthesizes HMG-CoA | Rate-limiting enzyme; statin target |
| HMGCR | HMG-CoA reductase; reduces HMG-CoA to mevalonate | Primary statin target; master regulator of cholesterol synthesis |
| MVK | Mevalonate kinase; phosphorylates mevalonate | Defects cause mevalonate kinase deficiency |
| PMVK | Phosphomevalonate kinase; forms mevalonate-5-diphosphate | Potential drug target in MVA pathway |
| MVD | Mevalonate diphosphate decarboxylase; produces IPP | Terminal step enzyme; engineering target |
| IDI1 | Isopentenyl diphosphate isomerase 1; converts IPP to DMAPP | Essential for isoprenoid diversity |
| FDPS | Farnesyl diphosphate synthase; condenses IPP and DMAPP | Target for bisphosphonates |
| GGPS1 | Geranylgeranyl diphosphate synthase | Prenylation of GTPases |
| PDSS1 | Decaprenyl diphosphate synthase subunit 1 | CoQ10 biosynthesis |
| PDSS2 | Decaprenyl diphosphate synthase subunit 2 | CoQ10 biosynthesis; mitochondrial function |
| COQ2 | 4-hydroxybenzoate polyprenyltransferase | CoQ10 biosynthesis; ferroptosis regulation |
| COQ10A | Coenzyme Q10 biosynthesis protein | Mitochondrial electron transport |
| SLC25A1 | Mitochondrial citrate carrier | Links TCA cycle to MVA pathway |
| SREBF2 | Sterol regulatory element-binding transcription factor 2 | Master transcriptional regulator of MVA genes |
| INSIG1 | Insulin-induced gene 1; regulates SREBP and HMGCR | Feedback control of cholesterol synthesis |
| SCAP | SREBP cleavage-activating protein | Senses sterols and regulates SREBP |
How Is isopentenyl diphosphate biosynthetic process, mevalonate pathway Regulated?
The mevalonate pathway is tightly regulated at multiple levels. Transcriptional control is mediated by SREBP-2 (SREBF2), which activates genes encoding HMGCR, HMGCS1, MVK, PMVK, MVD, and IDI1 in response to sterol depletion. Post-translational regulation of HMGCR includes sterol-induced degradation via INSIG1 and SCAP. Mitochondrial CoQ export under cholesterol biosynthetic stress is limited by mitochondria, revealing organelle crosstalk in pathway regulation. In cancer, the MVA pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification, indicating metabolic rewiring.
isopentenyl diphosphate biosynthetic process, mevalonate pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HMGCR | Liver cancer, ferroptosis suppression | HMGCR knockout hepatoma cell line; ferroptosis induction assays |
| COQ2 | CoQ10 deficiency, mitochondrial disease | COQ2 knockout cells; CoQ10 rescue |
| MVK | Mevalonate kinase deficiency | MVK point-mutation knock-in cells |
| PDSS2 | CoQ10 deficiency, nephropathy | PDSS2 knockout podocytes |
| SREBF2 | Dyslipidemia, cancer metabolism | SREBF2 overexpression and knockout models |
Liver Cancer and Ferroptosis Suppression
The mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification. This identifies HMGCR and downstream enzymes as potential therapeutic targets in hepatocellular carcinoma.
Cardiovascular Disease and Statin Therapy
HMGCR is the target of statins, which lower cholesterol by inhibiting the mevalonate pathway. This pathway is central to cardiovascular risk management and is a paradigm for metabolic drug discovery.
Mitochondrial CoQ10 Deficiency and Cholesterol Stress
Mitochondria limit coenzyme Q export under cholesterol biosynthetic stress, linking the MVA pathway to mitochondrial dysfunction and CoQ10 deficiency disorders.
Mevalonate Kinase Deficiency
Mutations in MVK cause mevalonate kinase deficiency, an autoinflammatory disorder, highlighting the clinical importance of the pathway.
From isopentenyl diphosphate biosynthetic process, mevalonate pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is HMGCR required for liver cancer cell survival? | HMGCR knockout cell line |
| Does a specific MVK mutation cause autoinflammation? | MVK point-mutation knock-in |
| Can CoQ10 rescue ferroptosis sensitivity? | COQ2 knockout + CoQ10 supplementation |
| How does SREBP-2 regulate MVA genes? | SREBF2 overexpression and knockout |
| What is the role of IDI1 in isoprenoid flux? | IDI1 knockout and tagged knock-in |
| Does mitochondrial CoQ export depend on MVA flux? | PDSS2 knockout with cholesterol stress |
How to Study the isopentenyl diphosphate biosynthetic process, mevalonate pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Levels of mevalonate, IPP, and isoprenoids | Pathway flux analysis |
| 13C isotope tracing | Carbon flux through MVA pathway | Metabolic engineering |
| HMGCR activity assay | Enzymatic reduction of HMG-CoA | Statin and inhibitor testing |
| RNA-seq | Expression of MVA genes | SREBP-2 target validation |
| Proteomics | Protein abundance of pathway enzymes | Post-transcriptional regulation |
| CRISPR knockout screen | Gene essentiality in MVA pathway | Cancer and ferroptosis studies |
| CoQ10 quantification | Coenzyme Q10 levels | Mitochondrial function |
| Ferroptosis assay | Lipid peroxidation and cell death | Cancer therapy response |
Metabolomics and Isotope Tracing
Metabolomic profiling and 13C-isotope tracing can quantify flux through the mevalonate pathway and identify intermediates such as mevalonate, mevalonate-5-phosphate, and IPP. These methods are essential for validating pathway activity in knockout and overexpression models.
Enzyme Activity Assays
In vitro enzyme assays for HMGCR, MVK, PMVK, and MVD measure catalytic activity and are used to characterize point mutations and inhibitors. Multienzyme bioreactor systems allow reconstitution of the entire pathway.
Transcriptomics and Proteomics
RNA-seq and proteomics reveal expression changes in MVA pathway genes under cholesterol stress or in cancer. SREBP-2 target gene signatures are commonly assessed.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout screens can identify MVA pathway genes required for cell growth, ferroptosis resistance, or CoQ10 production. These screens link genotype to metabolic phenotype.
How CRISPR Can Be Used to Study GO:0019287 isopentenyl diphosphate biosynthetic process, mevalonate pathway
Knockout
CRISPR knockout of HMGCR, MVK, MVD, or COQ2 enables loss-of-function studies to determine essentiality in cancer cell proliferation, ferroptosis resistance, and CoQ10 production. Knockout models are foundational for causal inference in MVA pathway biology.
Point Mutation
Point-mutation knock-in of specific residues in MVK or HMGCR can model inherited disorders such as mevalonate kinase deficiency and statin resistance. These models allow precise structure-function analysis.
Knock-in
Tagged knock-in of endogenous MVA enzymes (e.g., HMGCR-HA, MVD-FLAG) enables localization, interaction, and degradation studies under physiological expression. Knock-in reporters can track pathway activity in real time.
Overexpression
Overexpression of SREBF2, HMGCR, or IDI1 can drive pathway flux and is used to study cholesterol synthesis, isoprenoid production, and cancer metabolism. Overexpression models are valuable for metabolic engineering.
How EDITGENE Supports isopentenyl diphosphate biosynthetic process, mevalonate pathway Research
Researchers studying isopentenyl diphosphate biosynthetic process, mevalonate pathway-related genes often need to determine whether a candidate gene is causally involved in IPP production, cholesterol synthesis, CoQ10 generation, or ferroptosis regulation. EDITGENE provides publication-ready CRISPR models to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for isopentenyl diphosphate biosynthetic process, mevalonate pathway research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| HMGCR Knockout HAP1 Cell Line | EDJ-KQ78114 | Human | 3156 | Details Get a Quote |
| HMGCR Knockout HEK293T Cell Line | EDJ-KQ78152 | Human | 3156 | Details Get a Quote |
| HMGCR Knockout Hep-G2 Cell Line | EDJ-KQ78153 | Human | 3156 | Details Get a Quote |
Displaying Records 1 To 3 Of 3 Records
Frequently Asked Questions About isopentenyl diphosphate biosynthetic process, mevalonate pathway
What is GO:0019287?
GO:0019287 is the Gene Ontology term for the isopentenyl diphosphate biosynthetic process via the mevalonate pathway, which converts acetyl-CoA to IPP through mevalonate intermediates.
What genes are involved in the mevalonate pathway?
Key genes include HMGCR, HMGCS1, MVK, PMVK, MVD, IDI1, FDPS, and COQ2, among others.
What is the difference between the mevalonate and MEP pathways?
The mevalonate pathway uses acetyl-CoA and mevalonate, while the MEP/DOXP pathway uses pyruvate and glyceraldehyde-3-phosphate and is mevalonate-independent.
Why is IPP important?
IPP is the fundamental five-carbon unit for all isoprenoids, including cholesterol, CoQ10, dolichols, and prenylated proteins.
How is the mevalonate pathway regulated?
It is regulated by SREBP-2 transcriptionally and by HMGCR degradation via INSIG1 and SCAP.
What diseases are linked to the mevalonate pathway?
Liver cancer, cardiovascular disease, mevalonate kinase deficiency, and CoQ10 deficiency disorders.
How can I study the mevalonate pathway with CRISPR?
Use knockout, point-mutation, knock-in, or overexpression models to test gene function in IPP production and disease phenotypes.
What is the role of CoQ10 in the mevalonate pathway?
CoQ10 is a downstream isoprenoid product that suppresses ferroptosis and supports mitochondrial electron transport.
Can the mevalonate pathway be targeted for cancer therapy?
Yes, inhibiting the pathway can induce ferroptosis in liver cancer cells, suggesting therapeutic potential.
What model systems are used to study GO:0019287?
Cell lines with CRISPR knockouts, knock-ins, overexpression, and metabolic flux assays are commonly used.
Conclusion
GO:0019287 (isopentenyl diphosphate biosynthetic process, mevalonate pathway) is a central metabolic pathway that produces IPP, the universal isoprenoid precursor. Its dysregulation is implicated in cancer, cardiovascular disease, and mitochondrial disorders, making it a high-value target for research and drug discovery. CRISPR-based models provide powerful tools to dissect the causal roles of MVA pathway genes and accelerate therapeutic development.
References
- 1. Chen Y et al.. 2025. Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification.. J Hepatol 83(6):1338-1352 PMID: 40653112
- 2. Kang A et al.. 2016. Isopentenyl diphosphate (IPP)-bypass mevalonate pathways for isopentenol production.. Metab Eng 34:25-35 PMID: 26708516
- 3. Lange BM et al.. 1999. Isopentenyl diphosphate biosynthesis via a mevalonate-independent pathway: isopentenyl monophosphate kinase catalyzes the terminal enzymatic step.. Proc Natl Acad Sci U S A 96(24):13714-9 PMID: 10570138
- 4. Eisenreich W et al.. 2001. Deoxyxylulose phosphate pathway to terpenoids.. Trends Plant Sci 6(2):78-84 PMID: 11173292
- 5. Hedl M et al.. 2004. Inhibition of the class II HMG-CoA reductase of Pseudomonas mevalonii.. Protein Sci 13(6):1693-7 PMID: 15152097
- 6. Frank A et al.. 2017. The Methylerythritol Phosphate Pathway to Isoprenoids.. Chem Rev 117(8):5675-5703 PMID: 27995802
- 7. Sutherlin A et al.. 2004. Multienzyme mevalonate pathway bioreactor.. Biotechnol Bioeng 87(4):546-51 PMID: 15286992
- 8. Ndoci M et al.. 2026. Mitochondria limit coenzyme Q export under cholesterol biosynthetic stress.. J Cell Biol 225(8) PMID: 42257675
